Kardi Ai Raises CZK 130M at CZK 600M to Fund Expansion

By Grace Kim

Kardi Ai raised CZK 130 million in a Series A at a CZK 600 million post-round valuation, the Czech startup said on November 11, 2026. Callisto Health, a German health-technology venture fund, led the round, which Kardi Ai called the largest financing to date among Czech medtech startups.

What did the Series A fund?

Kardi Ai said the proceeds will support further expansion in Europe and Asia and development of models intended to estimate cardiac-arrhythmia risk. The Seed Starter programs of Česká spořitelna and Slovenská sporiteľňa joined the round with BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels.

Purple Ventures led Kardi Ai’s seed round in 2023, and BrightCap Ventures led its pre-seed round in 2022. Kardi Ai also said the financing would support validation of new models across global markets and different patient demographics.

Callisto Health managing director Stefan Eckhardt said the product “combines a certified medical device, ease of use and medical benefit,” and noted its “existing use in routine practice in Central and Eastern Europe.”

In practical terms, the round funds distribution first and regulatory validation for new software later.

How does the ECG system work?

Kardi Ai combines a sports chest strap containing an electrocardiogram sensor, a mobile application and AI analysis of ECG recordings. Users can wear the device during ordinary daily activities, view results and make the information available to a physician.

The company says the system does not itself establish a diagnosis. Instead, it supplies information for decisions about further care. Longer recordings can help capture intermittently occurring arrhythmias that a short examination may miss.

Kardi Ai reports these adoption and alert figures in Czechia:

• More than 70 hospitals.
• More than 20 corporate and employee-benefit partners.
• More than 6,000 users of the technology.
• Approximately one-quarter received an alert about a possible arrhythmia during long-term monitoring.
• More than 500 detections were assessed as critical.

With more than 6,000 users, Kardi Ai has scale in Czechia, but it still positions alerts as decision support rather than diagnoses.

Which markets come next?

Kardi Ai said it operates in Czechia, Slovakia, Poland, Romania and Bulgaria. The company reported these expansion plans:

• Germany: Kardi Ai is preparing a launch after completing pilot projects.
• Slovakia: More than 20 physicians, mainly cardiologists, work with the company after its entry through a local distributor.
• India: The country’s drug regulator, CDSCO, issued an MD-15 import licence covering Kardi Ai’s hardware and software in July 2026.
• Hyderabad: Kardi Ai plans to begin there after discussions with healthcare partners and continued commercial and logistics preparations. Operations are planned for the fourth quarter of 2026.
• United Arab Emirates: Kardi Ai reports holding a medical-device registration certificate from the UAE Ministry of Health and Prevention and is preparing market entry.
• Singapore: Medical-device approval remains in progress. Kardi Ai plans to use Singapore as an entry point to Southeast Asia, with the Philippines, Indonesia and Vietnam identified as subsequent target markets.

Kardi Ai can enter more markets with its existing monitor, while Singapore and the wider Southeast Asian push still depend on approvals.

When can earlier warnings reach patients?

Kardi Ai plans to build predictive models that use data from several measurements to estimate arrhythmia risk. The approach would extend the current technology beyond long-term monitoring and evaluation of heart rhythm. The models remain in development and must undergo expert validation and the applicable regulatory approval process before use in healthcare practice.

Chief executive Vlastimil Hrabal said the development goal is to “warn of elevated risk before an arrhythmia manifests.” He said the new capital will support validation across global markets and different patient demographics.

Kardi Ai’s expansion and model development now run on separate clocks. Market launches can build on the existing monitoring system, while clinical use of the proposed earlier-warning models depends on completing validation and regulatory approval.

The Series A gives Kardi Ai the capital to widen distribution, but its earlier-warning claims will not reach patients until the models pass expert validation and required regulatory approval.